Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
PF-00489791 For The Treatment Of Raynaud's
NCT01090492 · View on ClinicalTrials.gov ↗
Study Summary
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
Conditions Studied
Interventions
- DRUG PF-00489791
Study Locations (20)
Michigan
- University of Michigan — Ann Arbor
- University of Michigan Health System — Ann Arbor
- West Michigan Rheumatology, PLLC — Grand Rapids
New York
- The Center for Rheumatology — Albany
- Regional Rheumatology Associates — Binghamton
- AAIR Research Center — Rochester
Indiana
- Diagnostic Rheumatology and Research, PC — Indianapolis
- Memorial Health System, Inc. dba Memorial Medical Group Clinical Research Institute — South Bend
Maryland
- Johns Hopkins University - Division of Rheumatology — Baltimore
- The Center for Rheumatology and Bone Research — Wheaton
Pennsylvania
- East Penn Rheumatology Associates, PC — Bethlehem
- Altoona Center for Clinical Research — Duncansville
California
- Stanford Hospital and Outpatient Center — Redwood City
Connecticut
- University of Connecticut Health Center — Farmington
District of Columbia
- Georgetown University Hospital — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2010-08-04 |
| Est. Completion | 2011-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090492
The ClinicalTrials.gov registry entry for NCT01090492 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention — of which PF-00489791 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01090492 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Michigan, New York, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01090492 about?
NCT01090492 is a clinical study titled "PF-00489791 For The Treatment Of Raynaud's". The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
What is the current status of trial NCT01090492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2010-08-04. Estimated completion is 2011-05-31.
What conditions does trial NCT01090492 study?
This clinical trial studies the following conditions: Peripheral Vascular Disease, Raynaud's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01090492?
The interventions under investigation include: PF-00489791 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01090492?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01090492 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.